Lymphocyte antigen 6E is a protein that in humans is encoded by the LY6Egene.[5][6][7] Increased expression of Ly6E is associated with poor survival outcome in multiple malignancies as determined by a survey of more than 130 published clinical studies of gene expression studies on cancer tissue samples and adjacent normal tissues.[8] Ly6E is associated with drug resistance and tumor immune escape in breast cancer.[9] Further research is required to validate Ly6E for translation research. [1]
Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID8125298.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene. 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID9373149.
de Nooij-van Dalen AG, van Dongen GA, Smeets SJ, Nieuwenhuis EJ, Stigter-van Walsum M, Snow GB, Brakenhoff RH (2003). "Characterization of the human Ly-6 antigens, the newly annotated member Ly-6K included, as molecular markers for head-and-neck squamous cell carcinoma". Int. J. Cancer. 103 (6): 768–74. doi:10.1002/ijc.10903. PMID12516096. S2CID42182637.
